Topic Listing for Vivus

Ability Utilize Net Operating Loss Carryforwards Offset Future Abnormal Test Findings
Absence Established Market Common Stock Fair Value Shall Acceleration
Acceptance Possession Accomplishments
Accordingly Delivered Together Undelivered Treated Unit Accounting Since Accounting Certain Transactions Involving Stock Compensation Interpretation Apb
Accounting Changes Error Corrections-a Replacement Apb Opinion Fasb Accounting Impairment Disposal Long-lived Assets
Accounting Practice Accounting Stock Based Compensation
Accounting Stock Issued Employees Accounting System
Accounts Receivable Accounts Receivable Allowance Doubtful
Accounts Receivable Allowances Doubtful Cash Discounts Accumulated Deficit 1225 2004 Expect Continue Incur Substantial
Accumulated Deficit 1314 2005 Expect Continue Incur Substantial Accumulated Deficit 1400 2005 Expect Continue Incur Substantial
Accumulated Deficit 1460 2005 Expect Continue Incur Substantial Accumulated Deficit 1470 2005 Expect Continue Incur Substantial
Accumulated Deficit 1559 2006 Expect Continue Incur Substantial Accumulated Deficit 1617 2006 Expect Continue Incur Substantial
Accumulated Deficit 1679 2006 Expect Continue Incur Substantial Accumulated Deficit 1687 2006 Expect Continue Incur Substantial
Accumulated Deficit 1698 2007 Continue Incur Substantial Operating Accumulated Deficit 1731 2008 Continue Incur Substantial Operating
Accumulated Deficit 1733 2008 Continue Incur Substantial Operating Accumulated Deficit 1748 2007 Expect Continue Incur Substantial
Accumulated Deficit 1769 2008 Continue Incur Substantial Operating Accumulated Deficit 1798 2008 Continue Incur Substantial Operating
Accumulated Deficit 1802 2007 Continue Incur Substantial Operating Accumulated Deficit 1815 2007 Expect Continue Incur Substantial
Accumulated Deficit 1866 2009 Continue Incur Substantial Operating Accumulated Deficit 1998 2009 Continue Incur Substantial Operating
Accumulated Deficit 2208 2009 Continue Incur Substantial Operating Acrux
Acrux License Full Force Effect Actually Care Put Specific Approximation Number
Ada Presentation Adam Cutler Analyst
Additional Adverse Side Effects Individual Topiramate Phentermine Additional Adverse Side Effects Topiramate Phentermine
Additional Covenants Additional Findings Weight Loss
Additional Payments Additional Rent
Address Adjustable Rate
Adjustments Changes Capitalization Merger Change Control Adjustments Prevent Dilution
Administration Administrator Means Board Committees Shall Administering Plan Accordance
Adverse Changes Reimbursement Procedures Government Other Party Payors Adverse Changes Reimbursement Procedures Government Other Third-party Payors
Adverse Changes Reimbursement Procedures Medicare Other Third-party Payors Adverse Events
Adverse Side Effects Associated Topiramate Ingrediant Qnexa Result Adverse Side Effects Associated Topiramate Ingredient Qnexa Result
Adverse Side Effects Associated Topiramate Ingredients Qnexa Result Advertising Sales Promotion Expenses
Affiliates Borrower Affirmative Covenants
Again Really Bracket Entire Dose Range Dont Know Agent
Agreement Agreement Closing Without Prior Written Consent Acquiror Shall
Agreement Hereby Amended Entirety Read Follows Agreement Including Rights Duties Parties Hereto Shall Governed
Agreement Sale Real Estate Agreement Sell Evamist Rights Pharmaceutical
Agreements Airport Road Llc
Airport Road Llc New Jersey Limited Liability Alista
Allegations Discrimination Regardless Merit Negatively Affect Operations Causing Allegations Discrimination Wrongful Termination Other Employment Matters Regardless
Allocation Equity Compensation Allocation Treatment
Allocations Alterations Required Law
Amended Restated Option Put Agreement Amendment
Amendment Distribution Supply Agreement 2000 Between Vivus International Amendment Funding Royalty Agreement
Amendment Lease Amendment Rights Agreement
Amendments Articles Incorporation Bylaws Change Amount Such Claim Portion Thereof Becomes Finally Determined
Analysis Primary Endpoints Analysis Secondary Other Endpoints
Analyst Analyst Webcast
Announced Had Entered Definitive Agreement K-v Transfer Annual Bio Ceo Investor Conference
Annual Meeting Stockholders 2005 Annual Meeting Stockholders 2006
Annual Meeting Stockholders 2007 Annual Meeting Stockholders 2008
Appendix Applications Regulatory Approval Delayed Denied Due Problems Studies
Appointment Chief Operating Officer Appointment Vice President Chief Accounting Officer
Appointment Wesley Phd Vice President Clinical Development Approve Forms Agreement Plan
Assessments Municipal Improvements Asset Purchase Agreement
Assignment Assignment Buyer
Assignment Certain Intellectual Property Assignment Consideration Excess Rentals Defined
Assignments Assignments Participations Credit Reporting
Assume Assumed Liabilities Assumption Liabilities
Attachment Schedule Exceptions Attorneys Fees
Audit Committee Audit Fees
Audit-related Fees Authority Representatives
Authorized Signatures Completed Vote Counted Date Sign Below Authorized Signatures Sign Here Completed Instructions Executed
Authorized Signatures-sign Here-this Completed Instructions Executed Available Exemption Registration Requirements Applicable State Securities Blue
Available Information Available-for-sale Securities
Avanafil Avanafil Erectile Dysfunction
Avanafil Phase Data Avanafil Phase Studies
Award Means Individually Collectively Grant Plan Options Restricted Background
Background Statement Base Monthly Rent
Base Prospectus Base Salary
Because Such Dramatic Change Type Diabetes Treated Future Become Involved Securities Class Action Litigation Divert Managements
Become Subject Product Liability Claims Required Pay Damages Believe Current Sales Trends Diabetes Market Speak Importance
Believe Qnexa Groundbreaking Treatment Obesity Weight-related Co-morbidities Happy Beneficial Ownership Compliance
Beneficial Ownership Reporting Compliance Beneficially Owned Shares
Benefit Income Taxes Bio Ceo Investor Conference
Biometrics Blood Chemistry
Board Committees Board Directors Recommends Vote Following Proposals
Board Directors Stockholders Vivus Inc Board Directors Unanimously Approved Virgil Place Leland Wilson
Board Directors Unanimously Recommends Vote Approval Amendment 2001 Board Independence
Board Meetings Bonuses
Books Records Breaking Blind
Brokerage Commissions Business
Business Operations Suffer Event System Failures Business Overview
Cancellation Date Set Forth Award Agreement Unearned Restricted Cannot Protect Intellectual Property Rights Throughout World
Capital Appreciation Common Stock Sole Source Gain Investment Cardiovascular Risk Factors
Case Report Forms Case Report Forms Electronic Data Record
Cash Cash Bonus Payments Stock Option Awards Named Executives
Cash Bonuses Cash Equivalents
Cash Equivalents Available Sale Securities Cash Equivalents Available-for-sale Securities
Cash Paid Instead Issuing Fractional Shares Castro Mountain View Llc
Castro Street Castro Street Mountain View California 94040
Causality Assessment Cautionary Forward-looking Statements
Central Laboratory Selection Certain Anti-takeover Effects
Certain Cross-defaults Certain Information Incorporated Reference Proxy Statement Registrants 2005
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certain Statements Press Release Forward-looking Within Meaning Private Certificate Deposit
Certification Chief Executive Officer Financial Pursuant Usc 1350 Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act Change Control Agreements
Change Control Agreements Executive Officers Change Control Benefits
Change Control Means Occurrence Following Events Change Control Severance Agreement
Change Orders Change Registrants Certifying Accountants
Changes Accounting Standards Regarding Stock Option Plans Limit Changes Financial Accounting Standards Related Share-based Payments Expected
Changjin Wang Phd Charter Documents Delaware Law Make Acquisition Difficult Even
Choice Law Clear Market
Clearly Highlight Was Presentation Results Ob-202 Study Primary Clearly Medical Community Not Real Impact Slowing Progression
Clinic Practice Topiramate Plus Phentermine Clinical Candidate
Clinical Laboratory Tests Clinical Monitoring
Clinical Safety Clinical Services
Clinical Status Clinical Trial Agreements Sites Central Laboratory Edc Vendor
Clinical Trials Closed Transaction K-v Pharmaceutical Sale Product Candidate
Closeout Visits Closing
Closing Conditions Closing Date
Code Code Ethics
Coding Comfort Letters
Commercialization Manufacture Commitments
Common Stock Communications
Comparison Cumulative Total Return Comparison Cumulative Total Return Among Vivus Inc Nasdaq
Compensation Compensation Arrangements Non-employee Directors
Compensation Chief Executive Officer Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Components
Compensation Directors Compensation Process
Competition Completed End Phase Meeting Fda Qnexa
Completed Enrollment Phase Study Alista Completed Enrollment Pivotal Phase Clinical Study Investigational Drug
Completed Proprietary Formulation Development Qnexa Completed Spa Process Qnexa Phase Studies
Completion Acquisition Disposition Assets Completion Enrollment Phase Qnexa Obesity Studies
Compliance Compliance Changing Regulation Corporate Governance Public Disclosure Result
Compliance Insurance Requirements Compliance Laws
Compliance Laws Private Restrictions Compliance Securities Exchange Act 1934
Concentration Credit Risk Concentration Customers Suppliers
Conclusion Regarding Effectiveness Disclosure Controls Procedures Condemnation
Conditions Issuance Shares Conditions Landlords Consent
Conditions Lending Conditions Obligations Acquiror Closing
Conditions Obligations Seller Closing Conditions Precedent Purchase
Conference Call Conference Call Information
Conference Call Webcast Confidentiality
Conflict Conflicts Between Agreements
Conquer Ob-303 Conquer Ob-303 Study Overview
Conquer Trial Study Impact Qnexa Overweight Obese Patients Consent Independent Registered Public Accounting Firm
Consulting Services Consummation Sale Disposition Substantially Assets
Contact Contingencies Litigation
Continue Monitor Approved Drugs Required Complete Post-approval Studies Continue Monitor Approved Products Required Complete Post-approval Studies
Contracts Contractual Obligations
Contribution Controls Procedures
Corey Cosmo Jpmorgan Analyst Corporate Authority
Corporate Collaborations Licenses Parties Corporate Performance Graph
Corporate Secretary Vivus Inc 1172 Castro Street Mountain Corporate Strategy
Correcting Title Defects Cory Kasimov Jpmorgan Analyst
Cory Kasimov Jpmorgan Chase Analyst Cost Goods Sold
Cost Goods Sold Manufacturing Cost Goods Sold Manufacturing Expense
Counterparts Course Conference Call Vivus Make Projections Other Forward-looking
Covenants Covenants Parties
Cowen Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Policies Estimates Crown Bank Loan
Cumulative Remedies Setoff Current Global Economic Environment Poses Severe Challenges Business
Current Report Current Report Pursuant Securities Exchange Act 1934
Currently Depend Single Source Supply Alprostadil Interruption Harm Currently Depend Single Source Supply Laminated Foil Components
Currently Depend Single Source Supply Plastic Applicator Components Currently Global Shortage Acetonitrile Solvent Required Testing Verification
Cutting Fat New Approaches Obesity Data Central Laboratory
Data Entry Querying Data Management
Database Development Data Management Documents Date
Date 2006 Update Dated 2007
Deadline Receipt Stockholder Proposals Debarment
Debit Deerfield Corporation
Deerfield Financing Deerfield Transaction
Default Default Buyer
Default Seller Defaulting Underwriter
Defending Against Claims Relating Improper Handling Storage Disposal Definitely Not Theres Nothing Even Consideration Other Very
Definition Certain Terms Definition End Study
Definition Hospitalization Definitions
Definitions Incorporation Definitions Used Herein Following Terms Meanings Indicated
Delegation Authority Deliveries Closing
Delivery Possession Demise Leased Premises
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Departure Directors Principal Officers Election Appointment Departure Directors Principal Officers Election Appointment Compensatory
Depend Consultants Outside Contractors Extensively Important Roles Within Depend Exclusively Party Distributors Outside United States Very
Depend Exclusively Third-party Distributors Outside United States Very Dependent Collaborative Arrangements Strategic Alliances
Dependent Single Approved Therapeutic Approach Treat Erectile Dysfunction Deposit Moneys
Depository Description Real Estate
Descriptive Headings Context Diabetes
Diminution Value Profits Income Loss Business Reputation Opportunity Directors Executive Officers Corporate Governance
Disability Means Total Permanent Defined Code Disclaimer
Disclosure Data Discretion Proxies Authorized Vote Such Other Business Properly
Dispute Regarding Infringement Misappropriation Proprietary Rights Others Costly Dispute Resolution
Distribution Date Dividend Policy
Dividends Division Condemnation Award
Dm-230 Study Documentation
Documentation Concomitant Medication Documents
Documents Incorporated Reference Doesnt Necessarily Even Close View Results Got Duke
Dont Auction Rate Securities Portfolio Ken Drug Storage Accountability
Each Option Shall Designated Award Agreement Either Incentive Earning Statement
Earnings Per Share Effect Accounting Tax Treatment Compensation Decisions
Effect Landlords Consent Effect Vi-0521 Phentermine Topiramate Type Diabetes
Effectiveness Agreement Shall Become Effective Execution Delivery Hereof Efficacy Endpoints
Election Directors Electrocardiogram
Eliciting Adverse Event Information Eligibility
Email Copies Emphasize Again Things View Fda Changing
Employees Employment Agreement
Employment Agreements Encouraged Publication Revised Guidelines Reversal Fdas Historic Stance
End Phase Meeting Was Held Fda Regarding Testosterone End Results
End Treatment Visit Early Termination Energy Resource Consumption
Entered Collaboration Fund Phase Development Avanafil Oral Pde5 Entered Funding Collaboration Phase Studies Avanafil Erectile Dysfunction
Entire Agreement Entire Agreement Amendments
Entry Material Definitive Agreement Environmental Covenants
Environmental Protection Equate Ob-301 Phase Study
Equate Study Ob-301 Equate Trial Study Impact Qnexa Obese Patients Over
Equip Ob-302 Equip Ob-302 Conquer 0b-303 Phase Studies
Equip Ob-302 Results Equip Ob-302 Study Overview
Equity Compensation Equity Compensation Plan Information
Equity Compensation Plans Approved Stockholders Erectile Dysfunction
Erectile Dysfunction Program Erisa
Estimated Pre-vesting Forfeitures Estimates
Estoppel Certificate Estradiol Development Commercialization Agreement Fempharm Pty Ltd Acrux
Ethical Conduct Study Evamist
Evamist Books Records Evamist Fda Submissions Transfer Pursuant
Evamist Product Registrations Excluding Fda Submissions Subject Evamist Treatment Symptoms Associated Menopause
Even Investigational Product Candidates Receive Regulatory Approval United Even Receive Regulatory Approval Commercialize Drug Candidates Ability
Event Date Time 2008 130pm Event Feature Update Qnexa Avanafil Clinical Programs
Events Default Events Tenants Default
Exact Name Registrant Specified Charter Exchange Act
Exchange Listing Exchange Provision
Excluded Medications Exclusion Criteria
Execution Study Was Excellent Wish Thank Internal Staff Executive Compensation
Executive Officer Compensation Executive Officers
Executive Officers Directors Registrant Executive Time Off
Executives Failure Identify Board Such Identification Writing Appropriate Exercise Option
Exercise Price Per Share Shall 100 Fair Market Exercise Price Per Share Shares Issued Pursuant Option
Exercise Respect Put Right Specified Agreement Exercise Respect Put Rights Other Pursuant Agreement
Exhibits Expected Dividend
Expected Term Expected Volatility
Expenses Explanatory
Exposed Risks Related Collaborative Arrangements Licenses Strategic Alliances Exposed Risks Related Collaborative Arrangements Strategic Alliances
Extent Necessary Prosecuting Evamist Nda Obtaining Approval Face Additional Competition Outside United States Result Lack
Face Significant Governmental Regulation Product Development Activities Face Significant Risks Product Development Efforts
Fail Comply Healthcare Regulations Face Substantial Penalties Business Fail Retain Key Personnel Hire Train Qualified Employees
Failure Successfully Acquire Develop Market Additional Investigational Product Fair Market Value Means Date Common Stock Determined
Fair Value Fair Value Financial Instruments
Fair Value Measurement-definition Hierarchy Fair Value Measurements
Fda Accepts Phase Development Plan Qnexa Obese Patients Fda Other Regulatory Agencies Likely Require Extensive Expensive
Fda Other Regulatory Agencies Require Extensive Expensive Trials Fda Regulation
Federal Legislation Increase Pressure Reduce Prices Pharmaceutical Products Federal Reserve Board
Fees Billed Kpmg Llp 2004 2003 Fees Billed Kpmg Llp 2005 2004
Fees Billed Kpmg Llp 2006 2005 Fees Billed Odenberg Ullakko Muranishi Llp 2005
Fees Billed Odenberg Ullakko Muranishi Llp 2006 2005 Fees Billed Odenberg Ullakko Muranishi Llp 2007 2006
Female Sexual Arousal Disorder Female Sexual Arousal Disorder Phase Program Evamist
Female Sexual Health Fempharm Received Enforcement Fermpharm Patents Respect Evamist
Figure Measuring Tape Position Waist Circumference Assessments Final Prospectus
Final Supplement Financial Instruments Measured Fair Value
Financial Position Results Operations Cash Flow Subsidiaries Periods Financial Results
Financial Results 2004 Financial Results 2005
Financial Results 2006 Financial Results Conference Call
Financial Results Half 2005 Financial Results Particular Address Revenue Recognition 150 Received
Financial Statement Schedule Financial Statement Schedules
Financial Statements Financial Statements Exhibits
Financing Financing Activities
Financing Statements Findings Secondary Endpoints
Firm Stock Follow Ob-202 Study Initiated Additional Six-month Extension Dm-230
Following Limitations Shall Apply Grants Options Following Regulatory Approval Drug Candidates Subject Ongoing Obligations
Following Regulatory Approval Investigational Product Candidates Subject Ongoing Following Regulatory Approval Product Candidates Subject Ongoing Obligations
Force Majeure Foregoing Purposes Acts Such Attorney Being Hereby Ratified
Foreign Currency Exchange Economic Conditions Risk Form 10-k
Form 10-q Form 8-k
Form Deed Form Lock-up Agreement
Form Task Order Formation Qnexa Scientific Advisory Board
Formulation Packaging Forward Looking Statement
Forward-looking Statements Framingham Risk Score
Ftc Fundamental Changes
Funding Royalty Agreement Funding Royalty Agreement Hereby Replaced Entirety Following
Further Agreements Further Assurances
Future Future Accounting Requirements
Future Sales Common Stock Depress Price Gaddes Presentation Entitled
General General Limitations
General Philosophy General Provisions
General Waivers Get Them Confused Myself Answer Theyre Pleased Progress
Going Return Question Asked Few Ago See Whether Good Afternoon Thank Joining
Good Afternoon Thank Joining Know Difficult Times Economy Good Faith
Good Standing Governing Law
Government Chargebacks Rebates Sales Reserves Government Regulations
Graham Strachan Grant Key Patent Mdts Delivery System
Grant Security Interest Granted Vivus Acrux License Rights 517
Ground Lease Guess Wanted Step Back Lee Earlier Mentioned Potentially
Guy Marsh Hang
Headings Held 2005
Held 2008 Hematology
Hemoglobin Highlights
Holders Stock Other Securities Take Actions Contrary Interests Holding Over
However Hypoactive Sexual Desire Disorder
Ian Sanderson Analyst Ian Sanderson Cowen Analyst
Ilya Kravets Rodman Renshaw Analyst Imagine After Seeing Equate Enrollment Only What Look
Important Safety Information In-house Clinical Monitoring Activities
In-licensed Portion Rights Product Candidates Parties Default Material Inability Adequately Protect Proprietary Technologies Harm Competitive Position
Inclusion Criteria Income Taxes
Incorporated Documents Increase Chief Executive Officer Compensation
Increases Base Salary Compensation Named Executive Officers Indemnification
Indemnification Agreements Indemnification Contribution
Indemnification Medpace Indemnification Underwriters
Indemnification Vivus Indemnifications
Independent Contractor Index
Index Consolidated Financial Statements Index Exhibits
Inflation Information Disclosed Party Authorized Disclose
Initial Exercise Rights Initially Transferred Materials
Initiated Phase Diabetes Study Qnexa Initiated Phase Study Topiramate Phentermine Obese Patients Type
Initiated Pivotal Phase Trial Avanafil Treatment Erectile Dysfunction Initiation Extension Study Qnexa Diabetes
Initiation Research Coverage Cowen Wachovia Capital Markets Llc Inspection
Inspection Appraisal Inspections Audits
Institutional Review Board Institutional Review Board Initial Essential Documents Packages
Insurance Insurance Proceeds
Integration Intellectual Property
Intellectual Property Including Warranty Merchantability Noninfringement Fitness Particular Intellectual Property Support
Intentionally Deleted Interactive Voice Response System
Interest Calculation Interest Income
Interest Income Expense Interest Income Net
Interest Rate Interest Rate Risk
Internal Control Integrated Framework Internal Control-integrated Framework
Internal Meetings International
International Operations Internationally Through Distributors Information Clinical Trials Products Please
Internationally Through Distributors Treatment Erectile Dysfunction Information Clinical Introduction
Introduction Pro Forma Financial Information Inventories
Inventory Costs Inventory Costs Amendment Arb Chapter
Investigational Drug Candidates Investigational Product Candidate Qnexa Combination Drugs Approved Individually
Investigational Product Pipeline Update Investigators Meeting
Investing Activities Investment Cash Balance Investments Marketable Debt Securities Subject
Investment Clinical Development Manufacture Commercial Supply Qnexa Not Investor Relations Front Several Presentations Coming Include Presentation
Investor Representations Warranties Covenants Each Represents Warrants Agrees Investor Representations Warranties Covenants Each Severally Not Jointly
Investors Investors Read Risk Factors Set Forth Vivus Form
Irvivuscom Issuance Key European Patent Qnexa
Issuance Rights Certificates Expiration Issue
Issuer Free Writing Prospectus Jason Butler Rodman Renshaw Analyst
John Dietrich Phd Joint Several Liability
Joint Several Obligations Journal American Medical Association
Jurisdiction Venue Just Clarification European Supportive Studies Mentioned Youd Need
Just Clarify Did Correctly Understand Mitsubishi Tanabe Now Just Quick Question Once-daily Formulation Was Something Developed
Ken Trbovich Rbc Analyst Ken Trbovich Rbc Capital Markets Analyst
Key Data Known Adverse Side Effects Individual Topiramate Phentermine
Laboratory Tests Landlord Notice Address
Landlords Default Tenants Remedies Landlords Election
Landlords Insurance Landlords Insurance Costs
Landlords Obligation Landlords Remedies
Landlords Representations Landlords Right Enter
Landlords Right Terminate Largely Dependent Success Product Candidates Phase Clinical Development
Last Question Avanafil What Earliest Think Apply Nda Late Charge Interest Rent Default
Late Fee Launched Muse Alprostadil United States Together Partners
Launched Muse United States Together Partners Internationally Law
Lease Lease Commencement Date Term
Lease Commitments Leases
Lee Mentioned Developed Proprietary Once-a-day Formulation Qnexa Consists Lee Perry
Legal Description Mortgaged Premises Legal Description Property
Legal Existence Insurance Etc Legal Fees Expenses Additional Charges
Legal Impediment Issuance Legal Matters
Legal Proceedings Legal Services
Leland Wilson Leland Wilson President Chief Executive Officer
Leland Wilson Vivus Inc President Ceo Lender
Lender Liability Liabilities
License Agreements License Fees
License Other Revenue License Related Revenue
Liens Life Style Guidelines
Like Open Call Questions Limitation Landlords Liability
Limitation Landlords Liability Release Limitation Liability
Limitation Tenants Recourse Limited Liability Acknowledgment
Limited Sales Marketing Capabilities United States Linda Dairiki Shortliffe
Liquidity Capital Resources List Subsidiaries
Listing Events Default Litigation
Litigation Against Seller Little Control Over Wholesalers Buying Patterns Impact Future
Loan Documents Lock-up Agreements
Logan Luramist
Luramist Hypoactive Sexual Desire Disorder Luramist Testosterone Metered Dose Transdermal Spray Treatment Hypoactive
Maintenance Property Collectively Personal Expressly Excluding Owned Tenant Major Transactions
Make Other Determinations Deemed Necessary Advisable Administering Plan Male Sexual Health
Management Management Discussion
Managements Annual Report Internal Control Over Financial Reporting Managements Report Internal Control Over Financial Reporting
Manufacturing Manufacturing Agreements
Manufacturing Operations Currently Conducted Single Location Prolonged Interruption Manufacturing Other Agreements
Manufacturing Other Purchases Manufacturing Support Services
Margin Rules Mario Rosati
Market Interest Rate Risk Market Muse Legacy Product Prescription Treatment Erectile Dysfunction
Market Registrants Common Equity Related Stockholder Matters Issuer Market Risk
Markets Operate Highly Competitive Unable Compete Successfully Against Material Adverse Change
Material Adverse Effect Material Modification Rights Security Holders
Maximum Rate Interest Maybe Missed Providing Guidance Either Year-end Cash Estimated
Medical Writing Medpace Inc
Medpace Project Number Vob305 Medpace Shall Not Make Public Announcements Concerning Agreement
Medpace Task Order Number Meetings
Membership Menopausal Vasomotor Symptoms
Menopause Merger Reorganization Sale Assets
Merriman Curhan Ford Metabolic Syndrome
Metered Dose Transdermal Spray Mdts Patent Michelle Look Faafp San Diego Sports Medicine Family
Mike King Rodman Renshaw Mike King Rodman Renshaw Analyst
Milestones Minimis
Minutes Miscellaneous
Mitsubishi Tanabe Modification Agreement
Monitoring Data Review Guidelines Mortgage Other Collateral Guarantees
Mortgagee Protection Mortgages Fixtures Farm Products
Mountain View Calif Mountain View Calif 2006
Mountain View Calif 2007 Mountain View Calif 2008
Mountain View Calif 2009 Multiple Administrative Bodies Different Committees Respect Groups Service
Muse Muse Erectile Dysfunction
Muse Performance Muse Revenues
Muse Revenues Increased Same Period Last Increase Was Muse Revenues Increased Thats Same Last
Mutual Waiver Subrogation Mutual Written Agreement Seller Acquiror
Name Nasdaq
Nasdaq Vvus Nasdaqvvus
Natural Disasters Resource Shortages Disrupt Operations Adversely Affect Nda Submission
Need Obtain Fda Approval Proposed Product Name Qnexa Negative Covenants
Neil Gesundheit Mph Net Income Loss Per Share
Net Loss Income Per Share Newsletter
Next Question Comes Line Ken Trbovich Rbc Capital Nice Luxury Position Clearly Nda Approval Obesity Heavy
Noise Emissions Nominating Governance Committee
Nominees Director Non Solicitation
Non-serious Adverse Event Reporting Requirements Nonstatutory Stock Option Means Not Intended Qualify Incentive
Not Able Develop Commercialize Investigational Product Candidates Due Not Able Develop Commercialize Product Candidates Due Intellectual
Not Active Liquid Trading Market Common Stock Not Surprised Registry Because Label Whats Already Mentioned
Notes Payable Notes Payable Interest
Notice Annual Meeting Stockholders Held 2006 Notice Annual Meeting Stockholders Held 2007
Notice Grant Restricted Stock Units Notice Procedures
Notices Now Financial Results
Now Having Said Life Changing Very Quickly Fda Now Like Take Few Minutes Review Diabetes Important
Now Like Turn Call Over Leland Wilson President Now Like Turn Call Over Tim Morris Please
Now Like Turn Presentation Over Host Todays Call Now Therefore
Now Turn Call Back Lee Some Final Comments Now Turn Call Over Peter Tam Senior Vice
Now Turn Call Over Tim Number 0-23490
Number 001-33389 Ob-305
Obesity Obesity Diabetes
Objectives Obligation Each Investor Purchase Acquire Shares Hereunder Shall
Obligation Enter Agreement Shall Subject Conditions Ofac
Off-balance Sheet Arrangements Off-balance Sheet Financing Related Party Transactions
Officers Certificate Okay
Okay Guess Maybe Point Confusion European Studies Used Okay Other Questions Well Bring Getting Sign
Okay See Then Curious Mentioned Patients Able Dose Okay Thank Some Wonderful Questions Very Much
Open Conversation Questions Audience Operating Activities
Operating Leases Operating Results Fluctuate Fluctuation Cause Stock Price Decline
Operations Subsidiaries Considered Whole Otherwise Disclosed Contemplated Registration Operator
Operator Instructions Mike King Rodman Renshaw Opinion 10b-5 Statement Counsel
Opinion 10b-5 Statement Counsel Underwriters Opinions Counsel
Option Option Closing Date
Option Exercises Last Option Grants Last
Option Means Stock Granted Pursuant Plan Option Put Agreement
Optional Stock Oral Change
Oral Glucose Tolerance Test Organization Powers
Original Agreement Original Agreement Shall Amended Restated Entirety Read Follows
Ositive Phase Clinical Trial Results Evamist Other Administration Provided Above Plan Shall Administered Board
Other Agreements Other Events
Other Fees Other Government Regulations
Other Information Other Matters
Other Programs Other Restricted Medications
Other Restrictions Administrator Sole Discretion Impose Such Shares Other Revenue
Other Safety Studies Other Transactions
Outlook 2005 Outlook 2006
Outsource Several Key Parts Operations Interruption Services Provided Over Obese Patients Experienced Total Body Weight Loss
Overall Believe Great Transaction Parties Look Forward Initiation Overview
Ownership Improvements Paper Copies
Parent Means Corporation Whether Now Hereafter Existing Defined Parking
Partial Unenforceability Participate New Partnerships Other Strategic Transactions Impact Liquidity
Parties Parties Hereby Agree Prolong Validity Agreement Calendar 2011
Parties Liable Parties Shall Cooperate Effort Limit Issues Consideration Such
Party Beneficiary Patent Matters
Patent Rights Patents Proprietary Technology
Patients Current Diabetes Study Continue Additional Payment Expenses
Payment Purchase Price Payment Rent
Payment Schedule Payment Taxes
Payments Performance Incentive Plan 2007
Permits Permits Inspections
Permitted Permitted Exceptions
Perquisites Other Benefits Perry Serve Vice President Chief Accounting Officer
Personal Property Fixtures Peter Maybe Give Color Well
Peter Tam Peter Tam Vivus Inc Svp Product Corporate Development
Peter Tam Vivus Svp Product Corporate Development Pharmaceutical
Phase Double-blind Placebo-controlled Multicenter Extension Study Ob-303 Determine Phase Study Qnexa Type Diabetes Also Known Ob-202
Physical Condition Property Physical Examination
Placebo Subtracted Weight Loss Right Plain Vanilla
Plan Plans Place Address Not Going Too Much Plan
Plans Relates Additional Cash Expect Youll Once Youve Please
Pledge Federal Reserve Point Wouldnt Make Assumption
Policy Regarding Deductibility Compensation Portfolio Interest Exemption Certificate
Positive Alista Data Presented Annual Meeting American Urological Positive Clinical Data Demonstrates Early Muse Therapy Following
Positive Data Avanafil Nitrate Interaction Study Positive Data Avanafil Twice-daily Dosing Study
Positive Phase Clinical Trial Results Qnexa Novel Therapy Positive Phase Data Avanafil At-home Study
Positive Phase Data Testosterone Mdts Treatment Hsdd Positive Phase Data Testosterone Mdts Treatment Hypoactive Sexual
Possession Power Attorney
Preferred Share Purchase Rights Preferred Stock
Preliminary Prospectus Prepaid Expenses Other Assets
Prepaid Rent Preparation Dispensing
Prepayment Prepayments
Prescribe Amend Rescind Rules Regulations Relating Plan Including Presentation
Presentation Highlights Presentation Positive Results Key Avanafil Studies Sexual Medicine
Presentment Etc Preservation Collateral
Previously Was Global Shortage Acetonitrile Solvent Required Testing Price
Price Product Delivered Calendar 2004 2005 2008 Set Pricing Disclosure Package
Principal Accounting Fees Services Principles Consolidation
Prior Adoption Sfas 123 Prior Adoption Sfas 123r
Prior Association Fen-phen Lead Increased Scrutiny Prior Association Fen-phen Lead Increased Scrutiny Investigational Product
Private Restrictions Proceeds
Product Candidate Qnexa Combination Approved Drugs Commercially Available Product Candidate Qnexa Combination Drugs Approved Fda Commercially
Product Pipeline Product Returns
Product Returns Rebates Sales Reserves Product Revenue
Project Budget Payment Schedule Terms Project Schedule
Project Specifications Project Website
Promises Seller Properties
Property Property Equipment
Property Maintenance Costs Property Mortgaged
Property Operating Expenses Property Plant Equipment
Property Subject Agreement Proposal
Proposal Ratification Appointment Independent Registered Public Accounting Firm Prospective Thought Leaders Well Regulators Regarding Characteristics Ideal
Prospectus Protection Mortgagees Security
Protocol Provided
Provided Further Provided However
Provision Income Taxes Provision Income Taxes Was Prepared Discrete Basis Essentially
Proxies Proxy Solicited Board Directors Annual Meeting 2009
Publication Study Results Purchase Agreement
Purchase Manufacturing Facility Purchase Price
Purchase Price Payment Purchase Sale Assets Grant Licenses Sublicense Agreement
Purchase Sale Delivery Offered Securities Purchases
Purpose Purpose Plan 2001 Stock Option
Pursuant Securities Exchange Act 1934 Put Right
Qnexa Qnexa Diabetes
Qnexa Diabetes Ob-202 Study Qnexa Obesity
Qnexa Other Indications Qnexa Phase Obesity Program
Qnexa Phase Trial Results Qnexa Program Update Conference Call
Qnexa Reduces Hemoglobin A1c Percent Qnexa Subjects Had Weight Loss Percent Significant Improvement
Qnexa Treatment Group Had Study Completion Rate Most Qnexa Treatment Obesity
Qnexa Treatment Resulted Improved Glucose Control Obese Non-diabetic Qnexa Treatment Results Improved Glucose Control Obese Non-diabetic
Qnexa Update Quality Control Assurance
Quantitative Qualitative Disclosures Market Risk Quantity Ordered Delivery Eleventh Thirteenth Fifth Teen Agreement
Question Answer Question Audience Inaudible
Question Comment Audience Inaudible Questionnaire Assessments
Quorum Abstentions Broker Non-votes Raising 196 Through Sale Common Stock
Raising Additional Funds Issuing Securities Cause Dilution Existing Rate
Rationale Raw Material Supplier Fails Supply Active Pharmaceutical Ingredients
Raw Material Suppliers Fail Supply Active Pharmaceutical Ingredients Raw Material Suppliers Fail Supply Alprostadil Availability Limited
Real Property Taxes Realize However Current Economic Regulatory Climate Everything Minimize
Rebates Sales Reserves Receipt Copy
Receipt Milestone Payment European Distributor Recent Accounting Pronouncements
Recent Accounting Requirements Recent Clinical Development Highlights
Recitals Reclasses Level
Reclassifications Record Date Shares Outstanding
Record Retention Redemption
References Refunds Rights Related Taxes
Registration Compliance Stop Order Registration Statement
Registration Statement Form S-3 Registration Statement Prospectus
Regulation Disclosure Regulatory Correspondence
Regulatory Matters Reimbursement Underwriters Expenses
Related Party Transactions Rely Parties Conduct Clinical Trials Product Candidates Development
Rely Parties Conduct Pre-clinical Clinical Trials Studies Investigational Rely Parties Conduct Pre-clinical Clinical Trials Studies Product
Rely Parties Maintain Appropriate Levels Confidentiality Data Compiled Rely Parties Manufacture Sufficient Quantities Compounds Pre-clinical Clinical
Rely Parties Manufacture Sufficient Quantities Compounds Within Product Remainder Page Intentionally Left Blank
Remainder Page Left Blank Intentionally Remainder Page Left Intentionally Blank
Remedies Remedies Cumulative
Renewals Extensions Rent
Rent Other Charges Repair Maintenance
Replacement Documents Report Audit Committee
Report Audit Committee Board Directors Report Compensation Committee Board Directors
Report Independent Registered Public Accounting Firm Reporting Period
Reporting Requirements Reports
Representations Relating Representations Relating Bvi Fund
Representations Relating Stockholders Representations Warranties
Representations Warranties Acquiror Representations Warranties Covenants Agreements
Representations Warranties Covenants Hereby Represents Warrants Agrees Follows Representations Warranties Covenants Indemnification
Representations Warranties Seller Representatives
Reproduction Financing Statement Require Additional Capital Future Operating Plans Not Able
Required Vote Research Development
Research Development Expenses Research Development Expenses 2007 Increased Approximately Last Mainly
Research Development Expenses Accruals Reservations
Responsibilities Restoration
Restricted Cash Restricted Stock
Restricted Stock Means Shares Issued Pursuant Award Plan Restricted Stock Unit Agreement
Restricted Stock Units Restructuring Related Charges
Result Initial Paid Closing 140 Fda Approval Been Results
Results Current Future Clinical Testing Indicate Proposed Products Results Current Future Pre-clinical Studies Clinical Testing Trials
Results Current Pre-clinical Studies Clinical Trials Indicate Proposed Results Future Clinical Testing Indicate Proposed Products Not
Results Operations Results Operations Financial Condition
Results Pre-clinical Studies Completed Clinical Trials Not Necessarily Results Review Meeting
Retirement Savings Plan Revenue
Revenue Recognition Review Approval Ratification Transactions Related Parties
Revocability Proxies Right Buy Acquiring Shares
Right Buy Common Shares Right Outside Areas
Right Setoff Right Title Interest Seller Real Property Whether Owned
Rights Evidenced Common Share Certificates Rights Preferences Series Preferred
Rights Property Risk Factors
Risk Factors Affecting Operations Future Results Risk Loss
Risk-free Interest Rate Risks Related Fara
Risks Related Opa Risks Related Security Agreement
Risks Relating Financial Position Need Financing Risks Relating Operations
Risks Relating Transaction Deerfield Management Affiliates Ritu Baral Canaccord Adams Analyst
Routine Clinical Monitoring Visits Royalties
Rule Construction Rules Regulations
Ruth-anne Roussel Robbins Group Analyst Ruthanne Roussel Robins Group Analyst
Safety Analysis Safety Endpoints
Safety Tolerability Qnexa Determined Reporting Adverse Events Physical Salary
Sale Evamist K-v Pharmaceutical Sale Evamist Pharmaceutical
Sale Evamist Product Sale Evamist Rights K-v Pharmaceutical
Sales Accounts Instruments Sales Allowances Reserves
Sales Marketing Sales Marketing Support
Sales Transfers Same Manner Marked Signed Returned Proxy Voting Instruction
Sarbanes-oxley Act Schedule
Schedule 14a Schedule Securities Purchase Agreement
Screening Visit Securities
Securities Act Securities Purchase Agreement
Security Security Agreement
Security Agreements Security Deposit
Security Disposition Study Files Security Interest Collateral Obligations
Security Interest Property Security Ownership Certain Beneficial Owners Management
Security Ownership Certain Beneficial Owners Management Related Stockholder Seller
Seller Not Experienced Out-of-stock Back-order Situation Respect Evamist Sellers Representations Warranties
Selling General Administrative Selling General Administrative Expenses
Senior Management Promotions Seq
Serious Adverse Event Reporting Requirements Serious Adverse Events
Set Another Exciting Vivus Expect Significant Data Flow Setbacks Consolidation Pharmaceutical Biotechnology Industries Collaborators Inability Obtain
Severability Severance Benefits
Severity Assessment Share Ownership Concentrated Officers Directors Principal Stockholders Acting
Share Ownership Concentrated Officers Directors Principal Stockholders Exert Share-based Compensation
Share-based Compensation Expense Share-based Compensation-adoption Sfas 123r
Share-based Payment Share-based Payments
Shipping Handling Costs Signature
Signature Below Documents Reviewer Read Approved Attached Protocol Signatures
Signatures Following Page Signs
Simplified Site Audits
Site Initiation Visits Site Selection Pre-study Visits
Special Protocol Assessment Completed Agreement Reached Fda Safety Special Provisions
Sponsor Discontinuation Criteria Stabilization
Standards State New York Without Giving Effect Conflicts Laws
Statement Agreement Statistical Analysis
Status Reporting Step
Steve Sullivan Horizon Financial Group Analyst Steve Sullivan Horizon Financial Group Analyst Presentation
Steve Sullivan Horizon Management Analyst Stock Option Plan
Stock Option Plans Stock Options
Stock Performance Graph Stock Price Been Continue Volatile
Stock Price Decline Significantly Based Results Timing Clinical Stock Purchase Plan
Stockholder Approval Shall Obtain Plan Amendment Extent Necessary Stockholder Communications Directors
Stockholder Proposals 2008 Annual Meeting Stockholder Proposals 2009 Annual Meeting
Stockholder Rights Plan Stockholders
Stockholders Equity Stockholders Rights Prior Exercise
Studied Treatment Erectile Dysfunction Study
Study Closeout Study Conquer Obese Patients Bmi Greater Serious Co-morbidities
Study Design Study Evaluate Qnexas Effects Morbidly Obese Patients
Study Management Study Medication Supply Storage
Study Objectives Study Period
Study Procedures Study Start-up Team
Study Subjects Subcontracting
Subject Additional Risks Associated International Operations Subject Claims Employees Wrongfully Used Disclosed Alleged Trade
Subject Information Consent Subject Selection
Subject Withdrawal Sublicense Agreement
Sublicense Grants Submission Matters Vote Security Holders
Subordination Mortgages Subscription Agreement
Subscription Agreements Subsequent Events
Subsidiary Means Corporation Whether Now Hereafter Existing Defined Substitution Underwriters
Successful Completion Financing Raising 196 Successors Assigns
Successors Permitted Assigns Legal Equitable Right Remedy Claim Successors Persons Entitled Benefit Agreement
Sued Infringing Intellectual Property Rights Others Sued Infringing Intellectual Property Rights Others Infringe
Summary Stock Options Suppliers Fail Comply Fda Other Government Regulations Relating
Suppliers Fail Comply Fda Other Regulatory Agency Regulations Sure Just Something Thats Kind One-off Way Going
Surrender Possession Survival
Table Guidelines Adverse Event Reports Based Taking Defined
Taking Very Broad Approach Looking Partly Regulatory Meet Tanabe
Tanabe Line Credit Tax Adjustment Objections
Tax Insurance Escrow Tax Map Reference
Taxes Taxes Tenants Property
Temporary Taking Tenant
Tenant Notice Address Tenants Attornment Foreclosure
Tenants Financial Information Tenants Indemnification Landlord
Tenants Insurance Tenants Obligations
Tenants Right Terminate Tenants Waiver
Term Term Loan Agreement
Term Loan Purposes Term Termination
Termination Termination Material Definitive Agreement
Termination Release Terms Conditions Acrux License Whether Not Such Breach
Terry Nida Testosterone Mdts
Testosterone Mdts Treatment Hsdd Testosterone-mdts
Thank Course Conference Call Vivus Make Projections Other Thank Lee Mentioned Continue Make Excellent Progress Qnexa
Thank Operator Leland Final Thoughts Thanks Just Quick Tim Walk Through Terms Other
Thanks Lee Thanks Peter Now Financial Results
Thanks Taking Question Congrats Progress 2007 Thats Good True Patient Selection Very Critical Get
Thats Really Not Case Experience Then Lee Update Latest Thoughts Potential Partnerships Qnexa
Then Peter Just Provide Little Color Decision Immediate-release Think Youll Diabetes Efficacy Study Similar Terms Costs
Tim Morris Vivus Cfo Tim Morris Vivus Finance Cfo
Tim Morris Vivus Inc Cfo Time Essence
Time Further Questions Now Like Turn Call Back Time Now Like Turn Call Over Leland Wilson
Time Place Closing Timing Equity Awards
Timothy Morris Timothy Morris Vice President Finance Chief Financial Officer
Timothy Morris Vivus Cfo Timothy Morris Vivus President Ceo
Title Title Adverse Liens
Total Fixed Minimum Rent Additional Total Non-cash Compensation Expense Fas 123r Increase
Transfer Evamist Fda Submissions Shall Commercially Reasonable Efforts Transfer Information Development Evamist
Transfer Landlord Transfer Ownership
Transition Election Related Accounting Tax Effects Share-based Payment Transition Services Agreement
Trash Disposal Treatment
Treatment Diabetes Treatment Erectile Dysfunction
Treatment Visits Turn Call Back Lee Some Final Comments
Type Deed Type Diabetes Program
Type Equity Awards Ucc Financing Statement Amendment
Unable Close Sale Evamist Pharmaceutical Obtain Fda Approval Unable Collect Claim Reimbursement Product Establishment Nda Application
Unable In-license Intellectual Property Rights Technology Necessary Develop Underwriter
Underwriter Indemnified Party Underwriting Agreement
Unenforceability Unique Once-a-day Formulation Provides Increased Compliance Appealing Payers
United States United States Internationally Through Distributors Treatment Erectile Dysfunction
Urinalysis Urine Pregnancy Test
Used Future Research Development Activities Utilities
Valuation Valuation Assumptions
Valuation Technique Valuation Techniques
Value Investments Influenced Varying Economic Market Conditions Decrease Value Received
Victor Lau Wachovia Securities Analyst Virgil Place
Visit Only Vital Signs
Vital Signs Other Safety Evaluations Vivus
Vivus 2008 Vivus Agrees Quantity Product Purchased Chinoin Shall Event
Vivus Announces Abstract Published American Diabetes Association Scientific Vivus Announces New Data Qnexa Diabetes Study
Vivus Announces Podium Presentation Phase Data Qnexa Type Vivus Announces Positive Phase Clinical Trial Results Qnexa
Vivus Announces Positive Results Phase Study Avanafil Erectile Vivus Announces Presentation Qnexa Data 2008 Bio International
Vivus Announces Upcoming Webcasts Conference Participation Vivus Announces Weight Loss Effects Qnexa Type Diabetes
Vivus Completed Special Protocol Assessment Process Trial Spa Vivus Completes Enrollment Phase Equip Ob-302 Trial
Vivus Completes Special Protocol Assessment Phase Efficacy Studies Vivus Eligible Receive 150 Cash Payments Through Nda
Vivus Eligible Receive Milestone Payment 140000000 Pharmaceutical Vivus Enters Funding Collaboration Phase Studies Avanafil Erectile
Vivus Host Conference Call Webcast Discussion Avanafil Phase Vivus Host Event Live Webcast 2008
Vivus Host Investor Event Webcast Following Ada Presentation Vivus Inc
Vivus Inc 2007 Form 10-k Index Vivus Inc Adopts Stockholder Rights Plan Amends Bylaws
Vivus Inc Pioneer Research Development Proprietary Products Restore Vivus Inc Stockholder Meeting Held 2009
Vivus Initiates Pivotal Phase Trial Avanafil Treatment Erectile Vivus Initiates Pivotal Phase Trial Obese Patients Announces
Vivus Initiates Qnexa Phase Trial Obese Patients Vivus Initiates Qnexa Pivotal Phase Trial Obese Patients
Vivus Lease Extension Vivus Medpace
Vivus Obligations Vivus Participate Obesity Panel 2008 Rbc Capital Markets
Vivus Participate Panel 2007 Rbc Capital Markets Healthcare Vivus Present 2008 Merrill Lynch Global Healthcare Conference
Vivus Present 2008 Morgan Healthcare Conference Vivus Present 2008 Ubs Life Sciences Conference
Vivus Present 2008 Wachovia Healthcare Conference Vivus Present 2009 Morgan Healthcare Conference
Vivus Present Annual Bio Ceo Investor Conference Vivus Present Bio Ceo Investor Conference 2008
Vivus Present Biocentury Newsmakers Conference Vivus Present Cowen Annual Healthcare Conference
Vivus Present Cowen Healthcare Conference Vivus Present Financial Conferences
Vivus Present Jefferies Annual Healthcare Conference Vivus Present Merriman Curhan Ford Investor Summit 2008
Vivus Present Merriman Curhan Fords Investor Summit Vivus Present Noble Financial Conference
Vivus Present Upcoming Healthcare Conferences Vivus Real Estate Llc
Vivus Real Estate Llc New Jersey Limited Liability Vivus Reports 2004 Full-year Financial Results Late-stage Product
Vivus Reports 2005 Full-year Financial Results Vivus Senior Vice President Peter Tam Speak Obesity
Vivus Was Added Russell Microcap Index Vivuss Knowledge Infringement Fempharm Patents
Volatility Stock Prices Other Companies Contribute Price Vote Important
Vote Required Voting Solicitation
Wachovia Securities 2007 Healthcare Conference Waist Circumference Measurement
Waiver Waiver Amendments
Waiver Event Default Wall Street Journal
Warranties Covenants Survival Warranties Representations
Webcast Replay Weight
Weight Assessment Weight Assessment Waist Circumference Measurement
Wesley Phd Whereas
Whether Not Transactions Contemplated Agreement Consummated Terminated Pay While Entitled Future Milestone Payments Existing Contractual Arrangements
Wire Instructions Wiring Instructions
Withdrawals Due Adverse Events Witness Whereof
Witness Whereof Borrower Intending Legally Bound Executed Date Witness Whereof Mortgagor Intending Legally Bound Executed Mortgage
Witnesseth Written Modification Waiver
Wwwvivuscom Year-end Adjustments
Year-to-date 2006 Update Year-to-date 2008
Year-to-date 2009 Yes
Yes Working Through Clinical Research Organizations Speak Just Yes Wouldnt Get Too Hung Quarter-to-quarter Fluctuations
Youre Going Surprised Well Wait Until Announcement 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki